Sociodemographic associations with abnormal estimated glomerular filtration rate (eGFR) in a large Canadian city: a cross-sectional observation study

Irene Ma 1, Maggie Guo 6, Daniel Muruve 2,3, Hallgrimur Benediktsson 1,6 and Christopher Naugler 1,4,5,6*

Abstract

Background: Chronic kidney disease (CKD) is often asymptomatic in its early stages but is indicated and is diagnosed with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m². Certain sociodemographic groups are known to be at risk for CKD, but it is unclear if there are strong associations between these at risk groups with abnormal eGFR test results in Canada. Using only secondary laboratory and Census data, geospatial variation and sociodemographic associations with abnormal eGFR result rate were investigated in Calgary, Alberta.

Methods: Secondary laboratory data from all adult community patients who received an eGFR test result were collected from Calgary Laboratory Service’s Laboratory Information System, which is the sole supplier of laboratory services for the large metropolitan city. Group-level sociodemographic variables were inferred by combining laboratory data with the 2011 Canadian Census data. Poisson regression and relative risk (RR) were used to calculate associations between sociodemographic variables with abnormal eGFR. Geographical distribution of abnormal eGFR result rates were analyzed by geospatial analysis using ArcGIS.

Results: Of the 346,663 adult community patients who received an eGFR test result, 28,091 were abnormal (8.1%; eGFR < 60 ml/min/1.73m²). Geospatial analysis revealed distinct geographical variation in abnormal eGFR result rates in Calgary. Women (RR = 1.11, P < 0.0001), and the elderly (age ≥ 70 years; P < 0.0001) were significantly associated with an increased risk for CKD, while visible minority Chinese (RR = 0.73, P = 0.0011), South Asians (RR = 0.67, P < 0.0001) and those with a high median household income (RR = 0.88, P < 0.0001) had a significantly reduced risk for CKD.

Conclusions: Presented here are significant sociodemographic risk associations, and geospatial clustering of abnormal eGFR result rates in a large metropolitan Canadian city. Using solely publicly available secondary laboratory and Census data, the results from this study align with known sociodemographic risk factors for CKD, as certain sociodemographic variables were at a higher risk for having an abnormal eGFR test result, while others were protective in this analysis.

Keywords: Chronic kidney disease, Estimated glomerular filtration rate, Laboratory medicine, Census data, Geospatial mapping

* Correspondence: Christopher.Naugler@cls.ab.ca
1Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, 9, 3355 Research Rd NW, Calgary, AB T2L 2K8, Canada
4Department of Family Medicine, Cumming School of Medicine, University of Calgary, 9, 3355 Research Rd NW, Calgary, AB T2L 2K8, Canada
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Chronic kidney disease (CKD) represents a significant disease burden, with a prevalence of approximately 12.5% of adult Canadians and 15.2% of Americans affected [1, 2]. Patients living with CKD costs the Canadian health care system over $40 billion CAD per year, with US estimates of over $50 billion USD in Medicare costs [3, 4]. Early detection and management of CKD are critical for reducing comorbidities and mortality rates, as the condition may be reversible. Unfortunately, early identification of CKD is challenging, as patients with early stages of CKD are often asymptomatic, due to the variable and non-specific clinical presentation of the disease [5, 6]. In fact, CKD is often diagnosed serendipitously through other common comorbidities and risk factors, including diabetes mellitus, hypertension, and cardiovascular disease (CVD) [6–8], which often meant their disease has progressed without detection. Individuals with certain sociodemographic factors may also be more vulnerable to developing CKD than others. Evidence show a higher prevalence of CKD in some visible minorities and certain Indigenous populations in Canada and the United States [9–15]. Those with different levels of income, education and employment may also be vulnerable to developing CKD [16–19]. However, it is clear that sociodemographic risk factors for CKD is population- and region-specific, as demonstrated by a study showing that low income, but not level of education, was strongly associated with CKD in the United States, while low education level, but not low income, was strongly associated with CKD in the Netherlands [18].

Despite the challenges of early identification and complexity of CKD risk, CKD is indicated and can be diagnosed when an individual have an abnormal estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m². According to the most recent guideline released by Kidney Disease: Improving Global Outcomes (KDIGO), adults with eGFR < 60 ml/min/1.73m² is considered to be at a moderately increased risk to very high risk for CKD [6]. When measuring renal function, eGFR is currently the clinical standard worldwide over serum creatinine measurement alone, as age, sex, diet, medication use, muscle mass and body size differences among individuals can significantly affect the interpretation of an abnormal creatinine result [20]. Today, the most widely used equation to estimate GFR is the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eq. (21), which not only accounts for the patient’s serum creatinine values, sex, age and ethnicity, but is also more accurate in diagnosing earlier stages of CKD in patients who have a higher eGFR [21, 22]. As a result, many clinical laboratories use the CKD-EPI eGFR equation to diagnose CKD worldwide [1, 6, 23–25].

The purpose of this study is to evaluate the sociodemographic associations with CKD, a complicated chronic disease, using only one laboratory test result, an abnormal eGFR, in a Canadian healthcare setting. To our knowledge, we are the first to do this using a single laboratory test result for CKD, where we combined secondary laboratory data with publically available Canadian census data for a large metropolitan city of Calgary, Alberta. As CKD risk is population- and region-specific, geographic distribution of abnormal eGFR result rate in the city of Calgary will also be assessed.

Methods
Laboratory data sources
Calgary Laboratory Services (CLS) is the sole supplier of laboratory services for Calgary and its surrounding area in Alberta, performing on average 29 million tests annually for a catchment population of approximately 1.4 million individuals. All eGFR test results from adult community patients were obtained from the Laboratory Information System (LIS) from CLS for the 2011 calendar year. 2011 was chosen as at the time the study was conducted, the 2011 Census was the most recent Census Adult eGFR in Calgary is calculated by using a modified version of the CKD-EPI GFR eq. (21), where the patient’s age, sex and measured blood creatinine value are used in the equation, but not the ethnicity of the patient, as that variable is unattainable from laboratory requisitions. All blood creatinine assays performed in Calgary are calibrated using the isotope-dilution mass spectrometry (IDMS)-traceable method [6]. Thus, any adult community patient who received a creatinine laboratory report from CLS, also received an eGFR report, all of whom were represented in this cross-sectional observation study. Hospitalized patients who received a serum creatinine value were not included in this study. Only the first eGFR test result encounter per community patient was included in the study in order to prevent skewing the data with results from patients who required regular screening or surveillance of renal function using eGFR [26]. Patients with an abnormal eGFR test result (eGFR < 60 ml/min/1.73m²) in Calgary were then linked with 2011 Statistics Canada Census data to investigate any sociodemographic associations.

Census linkage
Group-level sociodemographic variables were inferred by combining laboratory data with Statistics Canada’s 2011 Census data, as described previously [27–30]. Briefly, individual-level sociodemographic variables, including date of birth (DOB), gender and Personal Health Number (PHN) were collected for each patient from the LIS. Each patient’s postal code was then determined using PHNs from the Alberta Health Services Registry. The patient’s postal code allows for linking the patient’s eGFR test results to the 2011 Canadian Census.
Dissemination Units (DU) in the city of Calgary. In Statistics Canada’s census data, DUs exist as polygons that represent the smallest geographical units containing 400–700 individuals within each dissemination area throughout Canada [31]. Patient confidentiality was not an issue in this study because potentially identifying information, such as PHN, were removed for the analysis of this study. Patient data with missing PHN were excluded from the study as the PHN is required to link to the 2011 Canadian Census. Group-level sociodemographic variables were then inferred from the DU within the city of Calgary. Group-level sociodemographic variables for this study were chosen based on plausible associations with abnormal eGFR or CKD [25, 32], which included: recent immigrant status (immigration within the last 5 years), Indigenous status (First Nations, Métis; 2 largest Indigenous populations in Calgary [33]), visible minorities (including “Black”, “South Asian”, “Chinese”; the 3 largest visible minority populations in Calgary [33]), employment rate (percentage of individuals employed), education level (individuals with at least some university education), and median household income (MHI). Each variable (age, gender, ethnicity, socioeconomic status (SES)), was individually controlled for by holding all other variables constant as a reference. Therefore, each variable studied in this model has all been adjusted for.

Statistical analysis
A Poisson regression (SAS v.9 software) was performed to identify any statistically significant associations between the sociodemographic factors (independent variable) and the proportion of abnormal eGFR test results, or known as the abnormal eGFR result rate (dependent variable) per DU. Abnormal eGFR result rate was calculated by dividing the number of abnormal eGFR test results (as defined by eGFR < 60 ml/min/1.73m²) by the total number of the first eGFR test encounter for the calendar year within each DU. The sociodemographic associations were represented by the risk ratio (RR), where a value over 1.0 suggested the independent variable in question had a higher risk of abnormal eGFR result rate when compared to its reference state. For individual-level variables, all age groups < 69 years of age and the female gender were compared to a reference state of age ≥ 70 year and the male gender, respectively. Age was broken down into 7 groups (see Table 1). Each group-level sociodemographic variable was compared to its respective reference state. For example, all Indigenous populations from the 2011 Census groups not included in the study were used as a reference for First Nations and Metis groups in this study. Therefore MHI was represented in units of $100,000 CAD. P < 0.05 was deemed statistically significant (SAS v. 9 software).

| Abnormal eGFR result rates in Calgary, Alberta in 2011 |
|-----------------------------------------------------|
| eGFR Test Result (n) | Abnormal eGFR Test Result (n) | Abnormal eGFR Result Rate (%) |
|----------------------|--------------------------------|--------------------------------|
| Total 346,663        | 28,091                         | 8.1%                           |
| Female 195,844       | 16,412                         | 8.4%                           |
| Age < 20 years 2,305 | 6                               | 0.3%                           |
| Age 20–29 years 21,616 | 111                           | 0.5%                           |
| Age 30–39 years 31,565 | 288                           | 0.9%                           |
| Age 40–49 years 38,423 | 835                           | 2.2%                           |
| Age 50–59 years 41,529 | 1,962                         | 4.7%                           |
| Age 60–69 years 28,613 | 3,076                         | 10.8%                          |
| Age ≥ 70 years 31,793 | 10,134                         | 31.9%                          |
| Male 150,819         | 11,679                         | 7.7%                           |
| Age < 20 years 1,522 | 4                               | 0.3%                           |
| Age 20–29 years 10,724 | 88                             | 0.8%                           |
| Age 30–39 years 20,224 | 254                           | 1.3%                           |
| Age 40–49 years 30,614 | 727                           | 2.4%                           |
| Age 50–59 years 37,052 | 1,580                         | 4.3%                           |
| Age 60–69 years 26,841 | 2,444                         | 9.1%                           |
| Age ≥ 70 years 23,842 | 6,582                         | 27.6%                          |
rate) or cold (low abnormal eGFR result rate) spots in 90, 95 and 99% confidence levels within DUs.

**Ethics statement**
Ethics approval for this study was received from the University of Calgary Conjoint Health Research Ethics Board (Ethics ID REB 13–0862).

**Results**
In 2011, 346,664 adult community patients received an eGFR test result, but one patient was excluded from the study as their DOB was missing. Of the 346,663 adult patients who received their first eGFR test encounter for the 2011 calendar year (56.5% female, 43.5% male), 28,091 patients had an abnormal result (eGFR < 60 ml/min/1.73m²). The abnormal eGFR result rate in Calgary in 2011 was 8.1% (8.4% female, 7.7% male). See Table 1 for further details.

In order to investigate sociodemographic associations with abnormal eGFR test results, sociodemographic risk factors known to be associated with CKD were studied. All individual level and group level sociodemographic variables analyzed were adjusted for, thus making any significant associations an independent risk contribution. Poisson regression revealed that women and the elderly (age ≥ 70 years) were significantly associated with an increased risk for eGFR < 60 ml/min/1.73m², suggesting increased risk for CKD. Meanwhile, Chinese, South Asians, and those with a high MHI had a significantly reduced risk for an abnormal eGFR result. For every $100,000 increase in MHI, risk for abnormal eGFR test results significantly decreased by 12%. Refer to Table 2 for further details.

In order to investigate geographic distribution of abnormal eGFR result rate, geospatial analysis was conducted (Fig. 1), and revealed statistically significant regional variations of abnormal eGFR result rates in Calgary, with statistically significant hot spots (high abnormal eGFR result rates) in the northwest, and southwest quadrants of the city of Calgary; as well as along the Bow River, just east of downtown Calgary. Significantly cold spots (low abnormal eGFR result rates) was observed in the inner city of Calgary on the southwest end of downtown, and the outer edges of the city.

**Discussion**
In this article, we present geospatial distribution, and sociodemographic risk associations with an abnormal eGFR result rate, suggesting the presence of chronic kidney disease. The methodology of combining secondary laboratory data with Statistics Canada’s Census data (27–29) revealed statistically significant differences in geospatial distribution of abnormal eGFR result rates within Calgary, Alberta. Statistically significant risk associations for abnormal eGFR result rates were also observed for specific sociodemographic groups in the

| Table 2 Association of sociodemographic variables with the abnormal eGFR result rate (eGFR < 60 ml/min/1.73m²) |
|---------------------------------------------------------------|
| Sociodemographic Variables | Risk Ratio (RR) | 95% CI    | Chi-Square | P-value |
| Female | 1.11 | 1.09–1.14 | 88.46 | <.0001 |
| Male* | 1.00 | Reference |       |         |
| Age < 20 years | 0.01 | 0.004–0.01 | 225.78 | <.0001 |
| Age 20–29 years | 0.02 | 0.018–0.02 | 2766.70 | <.0001 |
| Age 30–39 years | 0.04 | 0.03–0.04 | 5802.60 | <.0001 |
| Age 40–49 years | 0.08 | 0.07–0.08 | 8742.50 | <.0001 |
| Age 50–59 years | 0.15 | 0.15–0.16 | 10088.00 | <.0001 |
| Age 60–69 years | 0.34 | 0.33–0.35 | 4902.60 | <.0001 |
| Age ≥ 70 yearsb | 1.00 | Reference |       |         |
| Recent immigrant (within 5 years) | 1.03 | 0.82–1.29 | 0.05 | 0.8213 |
| Aboriginal – First Nations | 1.09 | 0.78–1.51 | 0.24 | 0.6221 |
| Aboriginal – Métis | 0.90 | 0.48–1.69 | 0.10 | 0.7463 |
| Visible minority Chinese | 0.73 | 0.60–0.88 | 10.72 | 0.0011 |
| Visible minority South Asian | 0.67 | 0.59–0.76 | 35.41 | <.0001 |
| Visible minority Black | 1.15 | 0.85–1.53 | 0.84 | 0.3608 |
| Median household income ($100,000 CAD) | 0.88 | 0.85–0.92 | 38.94 | <.0001 |
| Employment rate | 0.89 | 0.77–1.03 | 2.39 | 0.1222 |
| At least some university education | 0.88 | 0.77–1.01 | 3.36 | 0.0670 |

* Males were used as a reference group for females
b Age group ≥70 years of age were used as a reference group for all other age groups
city. To our knowledge, we are the first to validate known sociodemographic risk factors for CKD using a single laboratory test result – an abnormal eGFR.

The geospatial analysis conducted in Calgary demonstrated clear geographic differences in abnormal eGFR result rates, as supported by the regional-specificity of CKD prevalence associated with different sociodemographic factors [9–11, 13, 16–18, 36, 37]. It has been previously demonstrated that certain sociodemographic groups cluster in different parts of Calgary: those with a higher MHI and a higher level of education tend to live in the inner city of Calgary near downtown, while those with lower income, lower level of education, self-reported visible minorities and First Nations groups cluster in the northwest quadrant along the Bow River [28, 38]. This may explain why we observed significant cold (low proportion of eGFR < 60 ml/min/1.73m² result rates) and hot (high proportion of abnormal eGFR result rates) spots in these neighbourhoods, respectively. Another speculation as to why there are significant cold or hot spots in the remaining neighbourhoods, is that perhaps it is due younger families that tend to live in the newer neighbourhoods.
in the periphery of the city, while those living in the north-west and southwest quadrants in the hot spot areas may overlap with an older demographic. It is unlikely that these hot spots of abnormal eGFR result rates represent greater access to healthcare, as previous studies have shown that in Calgary, Alberta, those living in the neighbourhoods within the periphery of the city travel significantly shorter distances than those in the periphery of the city to phlebotomy sites [39], suggesting easier access to receive laboratory testing for those living inside the city limits. It is also unlikely the hot spots identified in the geomapping analysis represent higher population density, as Statistics Canada standardizes each DU into 400–700 individuals per polygon unit throughout the country [31]. However, as we could not quantitatively assess the sociodemographic associations with abnormal eGFR result rates from the geomapping model alone, we performed a separate analysis (Table 2) to investigate this.

Consistent with other findings, as reviewed by Cobo, et al. [40], there is a statistically significant higher risk of women and the elderly with abnormal eGFR (< 60 ml/min/1.73m²) in Calgary, with age having the strongest risk association. This is likely due to age-related changes, and the difference in muscle mass between genders, as both variables impact serum creatinine values, which influences eGFR measurement [41]. Also consistent with other studies [17–19, 42], our analysis showed having a higher income reduces the risk of having an abnormal eGFR result, suggesting a decreased risk for CKD. Specifically, for every increase of $100,000 in MHI, the risk for developing CKD decreases by 12% in our analysis. Although not significant, being employed and having higher levels of education also show a decreased risk in abnormal eGFR result rate in this study. As expected, those who have a higher income, who are employed and who have a higher level of education in Canada tend to be healthier, as these sociodemographic factors influence health-related behaviours [43].

Interestingly, those who are Chinese or South Asian (East Indian, Pakistani, Sri Lankan [44]) are at a statistically significant lower risk of abnormal eGFR result rates compared to other ethnicities, suggesting a lower risk for CKD compared to other visible minorities reported in Census Canada. This result is difficult to interpret due to the fact that some guidelines state that certain ethnicities, including “Asians”, are a risk factor for CKD progression. However, rarely is the “Asian” population clearly defined in other international guidelines [24, 25], whereas in this study, we observed strong sociodemographic associations with specific self-identified visible minorities. Perhaps there was a limitation to our ecological analysis as studies have recommended using a different eGFR equation to include an Asian coefficient to account for the difference in muscle mass between different ethnicities [45, 46], which is not accounted for in the widely used CKD-EPI eq. (21). Finally, there may be possible co-segregation with other unmeasured socioeconomic or clinical variables that also decreased the risk of CKD for these visible minorities in Calgary.

Although there was an increased risk for abnormal eGFR result rates in First Nations and visible minority Black populations in Calgary, the analysis did not show statistical significance. This is interesting as many studies find those who are Indigenous Canadian or from a Black visible minority are more susceptible for CKD, including end stage renal disease (ESRD) [10, 12, 17, 36, 47]. The discrepancies may be due to the fact that Indigenous Canadians who live in an urban centre, such as Calgary, have a higher socioeconomic status [48] and have a decreased prevalence of CKD that is associated with easier access to healthcare [10] when compared to Indigenous Canadians living in more rural areas of the province. It is also important to note that although there was a higher prevalence of Indigenous First Nations with ESRD in Alberta, this was not the case for earlier stages of CKD when compared to non-Indigenous First Nations [9]. Additionally, statistical significance may not have been reached due to the relatively small sample size of First Nations and Black visible minority groups living in Calgary, at < 3% of Calgarian population [9, 33, 48].

By investigating sociodemographic risk associations with an abnormal eGFR result rate using publicly available secondary laboratory and Census data, we observed similar known sociodemographic risk associations with CKD. As health is related to socioeconomic status (SES) [43], it is unlikely there is a wide-spread selection bias of eGFR testing for adult community patients in Calgary, as we only observed one of the three SES to have a significantly reduced risk of an abnormal eGFR result, suggesting a reduced risk for CKD.

Limitations
One limitation to our study is that we did not analyze other common risk factors or comorbidities associated with CKD, such as diabetes, CVD, or hypertension [6, 8]. However, most patients with CKD are not identified or diagnosed until at a later stage of CKD when symptoms are present, or through accidental findings from comorbidities associated with CKD [5, 6, 8]. Thus, eGFR measurement alone allows primary care providers to identify sociodemographic groups at risk for CKD at an earlier stage, and can potentially reverse CKD progression through prompt interventions. Another limitation in the study is that the LIS in CLS does not include the African American, or any ethnicity related coefficient in the CKD-EPI eq. (21), as information regarding ethnicity of the patient cannot be collected from laboratory requisitions. It may be of interest for researchers for Canadian jurisdictions to modify
the CKD-EPI equation to account for our diverse population, as others have done [46, 49]. Moreover, as our model included the first eGFR test encounter for the calendar year, our analysis may have included patients who had their eGFR test repeated for confirmation of CKD diagnosis, or have an advanced stage of CKD, also known as ESRD. Therefore, although we reported an abnormal eGFR result rate of 8.1% in Calgary in 2011, we were not able to investigate true CKD prevalence in this analysis. In future, it may be of interest to separate out the different categories of CKD, rather than including an abnormal eGFR flag of 0–60 ml/min/1.73m². Despite these limitations, our model of combining secondary laboratory data with Census data resulted in sociodemographic risk associations with abnormal eGFR result rates, which was validated by, and aligned with, known sociodemographic risk association with CKD.

Conclusions
In this cross-sectional observation study, there were statistically significant region-specific variations in abnormal eGFR result rates in a large Canadian city. Those who are female, or over the age of 70 were at a significantly higher risk for CKD, while those of visible minority Chinese or South Asian groups, or have a high median household income, were at a significantly lower risk for CKD in this analysis. Results from this study may be useful for policy makers to allow primary care providers to target at risk sociodemographic groups and neighbourhoods identified in this study through decreased eGFR for early identification of CKD progression. This study validated the methodology of using publically available census data and secondary laboratory data to investigate factors associated with CKD risk, which could be applied to investigate sociodemographic associations with other chronic disease conditions using only secondary laboratory data. It may be of interest to analyze and compare results from this study with other jurisdictions across Canada using the same model, as the results shown here may be specific to this particular jurisdiction.

Abbreviations
CKD: Chronic kidney disease; CKD-EPI: Chronic kidney disease epidemiology collaboration; CLS: Calgary laboratory services; CVD: Cardiovascular disease; DOB: Date of birth; DU: Dissemination unit; eGFR: Estimated glomerular filtration rate; ESRD: End stage renal disease; IDMS: Isotope-dilution mass spectrometry; LIS: Laboratory information system; MHI: Median household income; PHN: Provincial health number; RR: Relative risk; SES: Socioeconomic status

Acknowledgements
We would like to thank Chad Dumont for his research assistance for this study.

Funding
This study was supported by the Canadian Institutes of Health Research (CIHR) Foundation Scheme to CN, grant number R254781–333204. The funding body did not have a role in the design of the study, in the collection, analysis and interpretation of data, and in writing the manuscript.

Availability of data and materials
The datasets generated during and/or analyzed during the current study are not publically available due to confidentiality and ethics review board restrictions, but are available from the corresponding author on reasonable request.

Authors’ contributions
DM, HB, CN contributed substantially to study design and conception. MG contributed substantially to data acquisition and analysis. IM drafted the article. Additionally, all authors (IM, MG, DM, HB, CN) contributed substantially to data interpretation and analysis, revised the manuscript critically for important intellectual content, approved the final version to be published, and agreed to act as guarantors of all aspects of the work. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Ethics approval and waiver of consent for this study was received from the University of Calgary Conjoint Health Research Ethics Board (Ethics ID REB 13–0862).

Consent for publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, 9, 3535 Research Rd NW, Calgary, AB T2L 2K8, Canada. 2Department of Medicine, Cumming School of Medicine, University of Calgary, 9, 3535 Research Rd NW, Calgary, AB T2L 2K8, Canada. 3Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, 9, 3535 Research Rd NW, Calgary, AB T2L 2K8, Canada. 4Department of Family Medicine, Cumming School of Medicine, University of Calgary, 9, 3535 Research Rd NW, Calgary, AB T2L 2K8, Canada. 5Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 9, 3535 Research Rd NW, Calgary, AB T2L 2K8, Canada. 6Department of Laboratory Services, Calgary, AB, Canada.

Received: 9 March 2018 Accepted: 23 July 2018
Published online: 09 August 2018

References
1. Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H, et al. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ. 2013;185(9):E417–23.
2. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System - United States [Internet]. Vol. 2017. Available from: https://nccd.cdc.gov/CKD/. Accessed 29 Sept 2017.
3. Honeycutt AA, Segel JE, Zhuo X, Hoenig TJ, Imai K, Williams D. Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013;24(9):1478–83.
4. Manns B, McKenzie SQ, Flora A, Gignac PM, Geller LI, Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD) Network. The financial impact of advanced kidney disease on Canada Pension Plan and private disability insurance costs. Can J Kidney Heal Dis. 2017;4(1):11.
5. Campbell D, Weir MR. Defining, Treating, and Understanding Chronic Kidney Disease—A Complex Disorder. J Clin Hypertens. 2015;17(7):514–27.
6. Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3:1–150.
7. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–47.
8. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179(1):1154–62.
